Eledon Pharmaceuticals (ELDN)
NASDAQ:ELDN
ELDN Stock Chart & Stats
$3.22
-$0.17(-3.66%)
At close: 4:00 PM EST
$3.22
-$0.17(-3.66%)
Day’s Range― - ―
52-Week Range$1.35 - $4.60
Previous CloseN/A
Volume121.23K
Average Volume (3M)1.39M
Market Cap
$235.14M
Enterprise Value$170.87M
Total Cash (Recent Filing)$133.34M
Total Debt (Recent Filing)$641.00K
Price to Earnings (P/E)―
Beta1.15
Next Earnings
May 07, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding75,851,720
10 Day Avg. Volume1,105,359
30 Day Avg. Volume1,389,606
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.90
Price to Sales (P/S)0.00
P/FCF Ratio-1.98
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.44
Forecast
1Y Price Target
$7.33Price Target Upside127.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.86
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated Safety ProfileTegoprubart showed a favorable safety profile versus standard immunosuppression, with fewer rejection episodes, less new-onset diabetes, and no evidence of kidney, blood pressure, or neurological toxicity in treated patients.
Islet Transplant EfficacyTegoprubart produced rapid and sustained improvements in blood sugar control and led to insulin independence in investigator-led islet transplant patients, with no transplant rejection or new donor-specific immune responses reported.
Regulatory And Trial Advancement PotentialCompany engagement with the FDA to review islet transplant data and supportive biomarker results could enable agreement on a regulatory path and the design of a late-stage trial for tegoprubart.
Bears Say
Comparator Performance RiskIn the Phase two trial, the control drug tacrolimus performed better than expected, making it more difficult for tegoprubart to demonstrate a clear advantage on the primary kidney function measure.
Funding And Cash Runway RiskLimited cash runway given current cash burn creates uncertainty around timely program advancement and may necessitate external financing or development delays despite encouraging clinical signals.
Small Sample Size UncertaintyClinical findings are based on a small number of patients in both the Phase two and investigator-initiated studies, which increases uncertainty about whether observed benefits will replicate in a larger population.
Eledon Pharmaceuticals News
ELDN FAQ
What was Eledon Pharmaceuticals’s price range in the past 12 months?
Eledon Pharmaceuticals lowest stock price was $1.35 and its highest was $4.60 in the past 12 months.
What is Eledon Pharmaceuticals’s market cap?
Eledon Pharmaceuticals’s market cap is $235.14M.
When is Eledon Pharmaceuticals’s upcoming earnings report date?
Eledon Pharmaceuticals’s upcoming earnings report date is May 07, 2026 which is in 23 days.
How were Eledon Pharmaceuticals’s earnings last quarter?
Eledon Pharmaceuticals released its earnings results on Mar 19, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.203 by $0.093.
Is Eledon Pharmaceuticals overvalued?
According to Wall Street analysts Eledon Pharmaceuticals’s price is currently Undervalued.
Does Eledon Pharmaceuticals pay dividends?
Eledon Pharmaceuticals does not currently pay dividends.
What is Eledon Pharmaceuticals’s EPS estimate?
Eledon Pharmaceuticals’s EPS estimate is -0.18.
How many shares outstanding does Eledon Pharmaceuticals have?
Eledon Pharmaceuticals has 75,851,720 shares outstanding.
What happened to Eledon Pharmaceuticals’s price movement after its last earnings report?
Eledon Pharmaceuticals reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.203. Following the earnings report the stock price went up 1.053%.
Which hedge fund is a major shareholder of Eledon Pharmaceuticals?
Currently, no hedge funds are holding shares in ELDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eledon Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.33 (127.64% Upside)
$7.33 (127.64% Upside)
Blogger Sentiment
Bullish
ELDN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.54%
12-Months-Change
Fundamentals
Return on Equity
-46.46%
Trailing 12-Months
Asset Growth
3.56%
Trailing 12-Months
Company Description
Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
ELDN Stock 12 Month Forecast
Average Price Target
$7.33
▲(127.64% Upside)
Technical Analysis
Tvardi Therapeutics
―
Editas Medicine
―
Annexon Biosciences
―
Design Therapeutics
―
Tevogen Bio Holdings
―
Ownership Overview
0.03% Insiders
6.96% Mutual Funds
33.66% Other Institutional Investors
51.87% Public Companies and
Individual Investors